Cello Group plc (LON:CLL)‘s stock had its “buy” rating reiterated by analysts at FinnCap in a report released on Monday, June 19th. They currently have a GBX 132 ($1.72) target price on the stock. FinnCap’s target price points to a potential upside of 5.18% from the company’s previous close.
Separately, N+1 Singer restated a “buy” rating and set a GBX 131 ($1.71) target price on shares of Cello Group plc in a report on Wednesday, March 22nd.
Shares of Cello Group plc (LON:CLL) remained flat at GBX 125.50 during trading on Monday. 23,096 shares of the company’s stock traded hands. The firm’s market capitalization is GBX 109.36 million. Cello Group plc has a 52 week low of GBX 94.60 and a 52 week high of GBX 140.00. The firm’s 50-day moving average is GBX 132.22 and its 200 day moving average is GBX 118.06.
Cello Group plc Company Profile
Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.
Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with MarketBeat.com's FREE daily email newsletter.